|
- Pharmaceutical Research Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
- AbbVie - Wikipedia
In June 2015, AbbVie and Halozyme Therapeutics entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology, this was terminated in November 2016
- AbbVie Inc. (ABBV)
Find the latest AbbVie Inc (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing
- About AbbVie - Our Company | AbbVie
When we became our own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech
- AbbVie to end Calico collab, lays off researchers: Stat
AbbVie is ending an 11-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat Now, the intensive project—which is focused on age-related diseases
- Patient Assistance | AbbVie
AbbVie is committed to helping patients get the medicines they need That’s why we offer patient assistance programs that provide free AbbVie medicines to qualifying patients
- AbbVie Announces U. S. FDA Approval of EPKINLY® (epcoritamab-bysp) in . . .
AbbVie Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995
- AbbVie Stock Falls 4% -- What Investors Need to Know
AbbVie's third-quarter results were pretty strong, and the company increased its guidance It was not enough to impress the market, which apparently expected more from the drugmaker AbbVie's
|
|
|